Lantheus (NASDAQ:LNTH) Cut to Sell (D+) at Weiss Ratings

Weiss Ratings cut shares of Lantheus (NASDAQ:LNTH) from a hold (c-) rating to a sell (d+) rating in a research report report published on Saturday morning,Weiss Ratings reports.

LNTH has been the topic of a number of other reports. William Blair reissued a “market perform” rating on shares of Lantheus in a report on Wednesday, July 16th. Mizuho lowered their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. TD Cowen lowered their price target on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, September 15th. B. Riley lowered their price target on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, September 16th. Finally, Truist Financial set a $63.00 price target on shares of Lantheus and gave the stock a “hold” rating in a report on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $74.50.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $58.13 on Friday. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $3.95 billion, a PE ratio of 15.46 and a beta of 0.09. Lantheus has a twelve month low of $47.25 and a twelve month high of $118.21. The company has a 50-day moving average price of $54.18 and a two-hundred day moving average price of $71.34.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The firm had revenue of $92.51 million during the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. Equities analysts forecast that Lantheus will post 6.01 EPS for the current year.

Insider Buying and Selling

In related news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This trade represents a 49.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Rajiv A. Patel sold 3,365,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,812,000 shares of company stock worth $382,427,380 over the last ninety days. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lantheus

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Lantheus by 3.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider’s stock worth $1,162,000 after acquiring an additional 400 shares in the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of Lantheus by 24.7% during the second quarter. Harbor Capital Advisors Inc. now owns 190,008 shares of the medical equipment provider’s stock worth $15,554,000 after acquiring an additional 37,691 shares in the last quarter. State of Alaska Department of Revenue raised its stake in shares of Lantheus by 2.7% during the first quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider’s stock worth $794,000 after acquiring an additional 215 shares in the last quarter. Reinhart Partners LLC. raised its stake in shares of Lantheus by 16.4% during the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after acquiring an additional 197,719 shares in the last quarter. Finally, Swedbank AB raised its stake in shares of Lantheus by 11.0% during the first quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after acquiring an additional 121,500 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.